# Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

> **NCT02035124** · PHASE2 · WITHDRAWN · sponsor: **SCRI Development Innovations, LLC**

## Conditions studied

- Advanced Prostate Cancer

## Interventions

- **DRUG:** BKM 120
- **DRUG:** Cabazitaxel

## Key facts

- **NCT ID:** NCT02035124
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-04
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn due to slow accrual. No patients were enrolled.
- **Last updated:** 2016-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02035124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02035124, "Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02035124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*